AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37881628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal barrier healing
Number of subjects: 73
Study 37881628 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic and histologic remission
Number of subjects: 73
Study 37882059 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 0
Study 37882059 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT) - Estradiol valerate (1 mg) + Medroxyprogesterone acetate (2.5 mg)
Number of subjects: 0
Study 37882059 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 37882145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibler's method (circumferentially wrapped in transparent plastic sheeting over cotton blankets on an insulating foam mattress)
Number of subjects: 77
Study 37882145 — intervention group
Group type: COMPARATOR
Intervention: Warm air (forced-air convection via Snuggle Warm™ Pediatric Full Body mattress)
Number of subjects: 77
Study 37882145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibler's method
Number of subjects: 77
Study 37882145 — intervention group
Group type: COMPARATOR
Intervention: Warm air
Number of subjects: 77
Study 37882229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 1883
Study 37882229 — intervention group
Group type: COMPARATOR
Intervention: Placebo (or no TXA)
Number of subjects: 1883
Study 37882432 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus lenvatinib with belzutifan
Number of subjects: 0
Study 37882432 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus lenvatinib with quavonlimab
Number of subjects: 0
Study 37882432 — intervention group
Group type: COMPARATOR
Intervention: pembrolizumab plus lenvatinib without belzutifan or quavonlimab
Number of subjects: 0
Study 37882449 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 0
Study 37882449 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus enzalutamide
Number of subjects: 0
Study 37882668 — intervention group
Group type: EXPERIMENTAL
Intervention: Enitociclib, 30 mg intravenous once weekly
Number of subjects: 15
Study 37882706 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week nab-paclitaxel (125 mg/m2 on days 1 and 8)
Number of subjects: 94
Study 37882706 — intervention group
Group type: COMPARATOR
Intervention: 4-week nab-paclitaxel (125 mg/m2 on days 1, 8, and 15)
Number of subjects: 94
Study 37882706 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week nab-paclitaxel
Number of subjects: 94
Study 37882871 — intervention group
Group type: EXPERIMENTAL
Intervention: ProVate (novel, disposable, self-inserted vaginal device)
Number of subjects: 58
Study 37882871 — intervention group
Group type: COMPARATOR
Intervention: Commercially available ring pessary (control)
Number of subjects: 58
Study 37882974 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL) + Letrozole (LET)
Number of subjects: 42
Study 37882974 — intervention group
Group type: EXPERIMENTAL
Intervention: First subsequent therapy
Number of subjects: 42
Study 37883003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 16
Study 37883003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 37883059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 72
Study 37883059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with resistance exercise
Number of subjects: 72
Study 37883059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 72
Study 37883059 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 37883073 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly cabazitaxel (CBZ16), 16 mg/m2 plus G-CSF and daily prednisolone
Number of subjects: 196
Study 37883073 — intervention group
Group type: COMPARATOR
Intervention: Triweekly cabazitaxel (CBZ25), 25 mg/m2 plus G-CSF and daily prednisolone
Number of subjects: 196
Study 37883081 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic metronomic therapy (daily oral thalidomide, fenofibrate, celecoxib, alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide, intravenous bevacizumab, intraventricular therapy with alternating etoposide and cytarabine)
Number of subjects: 40
Study 37883081 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic metronomic therapy
Number of subjects: 40
Study 37883088 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct gloving (hand hygiene not required before donning gloves)
Number of subjects: 3790
Study 37883088 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct gloving
Number of subjects: 3790
Study 37883088 — intervention group
Group type: COMPARATOR
Intervention: Usual care (hand hygiene before donning nonsterile gloves)
Number of subjects: 3790
Study 37883088 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3790
Study 37883128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT) via telehealth
Number of subjects: 0
Study 37883128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT) in-office
Number of subjects: 0
Study 37883128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT) in-home
Number of subjects: 0
Study 37883128 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37883133 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous oxytocin
Number of subjects: 0
Study 37883133 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and child oxytocin and HPA axis functioning
Number of subjects: 0
Study 37883190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low initial myocardial 18F-dopamine-derived radioactivity (<6,000 nCi-kg/cc-mCi)
Number of subjects: 34
Study 37883190 — intervention group
Group type: COMPARATOR
Intervention: Normal myocardial 18F-dopamine-derived radioactivity
Number of subjects: 34
Study 37883190 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently low 18F-dopamine-derived radioactivity
Number of subjects: 34
Study 37883245 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-delivered heated Hatha yoga
Number of subjects: 0
Study 37883245 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37883329 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtubule-targeted agents
Number of subjects: 0
Study 37883329 — intervention group
Group type: EXPERIMENTAL
Intervention: Spindle focusing
Number of subjects: 0
Study 37883329 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug that increases CIN
Number of subjects: 0
Study 37883413 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine Information Helpline (MIH)
Number of subjects: 250
Study 37883413 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 250
Study 37883461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness only
Number of subjects: 0
Study 37883461 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and mindfulness
Number of subjects: 0
Study 37883682 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR), n=77
Number of subjects: 151
Study 37883682 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR), n=74
Number of subjects: 151
Study 37883682 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 151
Study 37883682 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 151
Study 37883682 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR and SAVR
Number of subjects: 151
Study 37883723 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker group (specific targeted agents plus paclitaxel)
Number of subjects: 318
Study 37883723 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard-of-care: paclitaxel with or without ramucirumab)
Number of subjects: 318
Study 37883723 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib addition for EGFR 3+ patients
Number of subjects: 318
Study 37883727 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin induction therapy
Number of subjects: 45
Study 37883734 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine (DFMO)
Number of subjects: 141
Study 37883734 — intervention group
Group type: COMPARATOR
Intervention: Control (historical rates from ANBL0032)
Number of subjects: 141
Study 37883739 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-Adjusted Therapy
Number of subjects: 0
Study 37883739 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37883738 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Neoadjuvant Therapy
Number of subjects: 0
Study 37883738 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37883795 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cells (CTL019) with time-limited ibrutinib, started before leukapheresis and continued for a minimum of 6 months post-CAR-T administration.
Number of subjects: 20
Study 37883795 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cells (CTL019) with time-limited ibrutinib
Number of subjects: 20
Study 37883784 — intervention group
Group type: EXPERIMENTAL
Intervention: ultrasound renal denervation (uRDN)
Number of subjects: 506
Study 37883784 — intervention group
Group type: COMPARATOR
Intervention: sham procedure
Number of subjects: 506
Study 37883802 — intervention group
Group type: EXPERIMENTAL
Intervention: rFXIII-A2 infusion
Number of subjects: 0
Study 37883802 — intervention group
Group type: COMPARATOR
Intervention: Free FXIII-B2
Number of subjects: 0
Study 37883803 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical bone marrow transplant (haplo-BMT)
Number of subjects: 11
Study 37883997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryocompression therapy on dominant hand and foot
Number of subjects: 69
Study 37883997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryocompression therapy
Number of subjects: 69
Study 37883997 — intervention group
Group type: COMPARATOR
Intervention: No intervention on opposite side (control)
Number of subjects: 69
Study 37883997 — intervention group
Group type: COMPARATOR
Intervention: Control side (no intervention)
Number of subjects: 69
Study 37884030 — intervention group
Group type: EXPERIMENTAL
Intervention: AVALUS group
Number of subjects: 140
Study 37884030 — intervention group
Group type: COMPARATOR
Intervention: CEPME group
Number of subjects: 140
Study 37884063 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab (anti-CD3)
Number of subjects: 80
Study 37884063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 37884121 — intervention group
Group type: EXPERIMENTAL
Intervention: I kua na'u intervention featuring culturally tailored videos and multiple educational sessions
Number of subjects: 220
Study 37884121 — intervention group
Group type: COMPARATOR
Intervention: Control group (110 people recruited from ambulatory clinics)
Number of subjects: 220
Study 37884121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-post study design among 110 people living on Hawaiian Homestead communities
Number of subjects: 220
Study 37884330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast Activation Protein-Targeted PET/CT
Number of subjects: 0
Study 37884337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) stimulation as an adjunct therapy to lumbar spinal fusion procedures
Number of subjects: 142
Study 37884415 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 Lot 1
Number of subjects: 923
Study 37884415 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 Lot 2
Number of subjects: 923
Study 37884415 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 Lot 3
Number of subjects: 923
Study 37884415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 923
Study 37884523 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib with HAIC-FOLFOX
Number of subjects: 35
Study 37884606 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus best supportive care
Number of subjects: 0
Study 37884606 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 0
Study 37884680 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital lifestyle treatment
Number of subjects: 331
Study 37884801 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 500
Study 37884860 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-FA-BCIP
Number of subjects: 800
Study 37884860 — intervention group
Group type: COMPARATOR
Intervention: Culture-based identification
Number of subjects: 800
Study 37884934 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a clinical decision support system (CDSS) based on Strong Inside Motivation, High Capability for Development, and Strong Outside Motivation.
Number of subjects: 224
Study 37884934 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a clinical decision support system (CDSS) based on Strong Inside Motivators, Many Options for Development, and absence of High Capability for Development.
Number of subjects: 224
Study 37884972 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain fatty acids (SCFAs) - acetate, propionate, butyrate delivered via pH-dependent colon-delivery capsules for six weeks
Number of subjects: 92
Study 37884972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 37884972 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain fatty acids (SCFAs)
Number of subjects: 92
Study 37885026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (IVI) - ferric derisomaltose
Number of subjects: 310
Study 37885026 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 310
Study 37885041 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacytidine-containing induction regimen
Number of subjects: 155
Study 37885041 — intervention group
Group type: COMPARATOR
Intervention: Non-azacytidine containing group
Number of subjects: 155
Study 37885103 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III obesity
Number of subjects: 823
Study 37885233 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium Soft Gelatin Capsules
Number of subjects: 0
Study 37885302 — intervention group
Group type: EXPERIMENTAL
Intervention: CARTOFINDER (CF) mapping
Number of subjects: 20
Study 37885445 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-ingredient herbal supplement (12 weeks)
Number of subjects: 0
Study 37885482 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanically-assisted gait training (HAL)
Number of subjects: 17
Study 37885482 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (CONV)
Number of subjects: 17
Study 37885795 — intervention group
Group type: COMPARATOR
Intervention: Primary series (2 doses)
Number of subjects: 1462
Study 37885795 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose (monovalent)
Number of subjects: 1462
Study 37885796 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive COVID-19 individuals
Number of subjects: 7405
Study 37885796 — intervention group
Group type: COMPARATOR
Intervention: Negative COVID-19 individuals
Number of subjects: 7405
Study 37886040 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential substance use treatment
Number of subjects: 0
Study 37886114 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy for 12 weeks
Number of subjects: 80
Study 37886114 — intervention group
Group type: COMPARATOR
Intervention: Play-based therapy for 12 weeks
Number of subjects: 80
Study 37886450 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal kits (n=35)
Number of subjects: 70
Study 37886450 — intervention group
Group type: COMPARATOR
Intervention: No-prep meals (n=35)
Number of subjects: 70
Study 37886450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 37886458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg PO plus standard treatment
Number of subjects: 0
Study 37886458 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 0
Study 37886579 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectric interface for neurorehabilitation (MINT) conditioning
Number of subjects: 9
Study 37886601 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcome assessments (COAs) for LGMD
Number of subjects: 188
Study 37886645 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin receptor (SSTR)-2+ treatment
Number of subjects: 27
Study 37886820 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification Day 3
Number of subjects: 161
Study 37886820 — intervention group
Group type: COMPARATOR
Intervention: Vitrification Day 5/6
Number of subjects: 161
Study 37886872 — intervention group
Group type: EXPERIMENTAL
Intervention: P2B001 (0.6 mg pramipexole and 0.75 mg rasagiline)
Number of subjects: 544
Study 37886880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6401
Study 37886880 — intervention group
Group type: COMPARATOR
Intervention: Control (no dapagliflozin)
Number of subjects: 6401
Study 37887061 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Zn levels above the 50th percentile (P50)
Number of subjects: 635
Study 37887530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) after lymphatic mapping with lymphoscintigraphy
Number of subjects: 0
Study 37887530 — intervention group
Group type: COMPARATOR
Intervention: Alternative techniques to lower the false negative rate (FNR) of SLNB
Number of subjects: 0
Study 37887560 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered behavioral intervention
Number of subjects: 0
Study 37887560 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 0
Study 37887871 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA with fast gantry speed (0.23 s/rot)
Number of subjects: 142
Study 37887871 — intervention group
Group type: COMPARATOR
Intervention: CCTA with standard gantry speed (0.28 s/rot)
Number of subjects: 142
Study 37887975 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (6 g/day)
Number of subjects: 50
Study 37887975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose, 6 g/day)
Number of subjects: 50
Study 37888524 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) training
Number of subjects: 48
Study 37888524 — intervention group
Group type: COMPARATOR
Intervention: Sham Blood Flow Restriction (sham BFR)
Number of subjects: 48
Study 37888524 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR training
Number of subjects: 48
Study 37888524 — intervention group
Group type: COMPARATOR
Intervention: Sham BFR
Number of subjects: 48
Study 37888839 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision sling
Number of subjects: 8051
Study 37888881 — intervention group
Group type: COMPARATOR
Intervention: Elective gallbladder operations (2019 vs 2020)
Number of subjects: 146
Study 37888881 — intervention group
Group type: COMPARATOR
Intervention: Elective liver resections (2019 vs 2020)
Number of subjects: 146
Study 37888881 — intervention group
Group type: COMPARATOR
Intervention: Elective pancreatic resections (2019 vs 2020)
Number of subjects: 146
Study 37888881 — intervention group
Group type: COMPARATOR
Intervention: Overall emergency workload (2019 to 2022)
Number of subjects: 146
Study 37888915 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting resorbable scaffold
Number of subjects: 261
Study 37888915 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 261
Study 37888914 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled amikacin (20 mg/kg ideal body weight once daily for 3 days)
Number of subjects: 847
Study 37888914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 days)
Number of subjects: 847
Study 37888914 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled amikacin
Number of subjects: 847
Study 37888914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study 37888917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab (60 mg initial dose, followed by 30 mg or 60 mg every 4 weeks for 16 weeks)
Number of subjects: 274
Study 37888917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 37888916 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran (0.3 mg/kg body weight, once every 3 weeks for 12 months)
Number of subjects: 360
Study 37888916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 37888913 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg daily)
Number of subjects: 2684
Study 37888913 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin)
Number of subjects: 2684
Study 37889100 — intervention group
Group type: EXPERIMENTAL
Intervention: PICU Supports intervention involving trained family navigators who assessed and addressed parent needs, offered weekly family meetings, and provided post-PICU discharge check-ins.
Number of subjects: 224
Study 37889107 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma with a neutralizing antibody titer of at least 1:320 (or 1:160 for 17.7% of patients)
Number of subjects: 475
Study 37889107 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 475
Study 37889176 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Radial Artery (dRA) access
Number of subjects: 300
Study 37889176 — intervention group
Group type: COMPARATOR
Intervention: Proximal Radial Artery (pRA) access
Number of subjects: 300
Study 37889176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 37889176 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in hand function
Number of subjects: 300
Study 37889172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin
Number of subjects: 6412
Study 37889172 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel-aspirin
Number of subjects: 6412
Study 37889180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined pericardial adipose tissue (PAT)
Number of subjects: 28161